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A close correlation exists between positron emission tomography (PET)-determined
histamine H1-receptor occupancy (H1RO) and the incidence of sedation. Antihistamines
with H1RO <20% are classified as non-sedating. The objective was to compare the H1RO of
bilastine, a second generation antihistamine, with that of hydroxyzine.
METHODS
This randomized, double-blind, crossover study used PET imaging with [11C]-doxepin to
evaluate H1RO in 12 healthy males (mean age 26.2 years), after single oral administration of
bilastine (20 mg), hydroxyzine (25 mg) or placebo. Binding potentials and H1ROs were
calculated in five cerebral cortex regions of interest: frontal, occipital, parietal, temporal,
insula. Plasma bilastine concentrations, subjective sedation (visual analogue scale),
objective psychomotor performance (digital symbol substitution test), physiological
variables and safety (adverse events, AEs), were also evaluated.
RESULTS
The mean binding potential of all five regions of interest (total binding potential) was
significantly greater with bilastine than hydroxyzine (mean value 0.26 vs. 0.13, P < 0.01;
mean difference and 95% CI −0.130 [−0.155, 0.105]). There was no significant difference
between bilastine and placebo. Overall H1RO by bilastine was significantly lower than that
by hydroxyzine (mean value −3.92% vs. 53.95%, P < 0.01; mean difference and 95% CI
57.870% [42.664%, 73.075%]). There was no significant linear relationship between
individual bilastine plasma concentrations and total binding potential values. No significant
between-treatment differences were observed for sedation and psychomotor performance.
Twenty-six non-serious AEs were reported. Sleepiness or sedation was not reported with
bilastine but appeared in some subjects with hydroxyzine.
CONCLUSIONS
A single oral dose of bilastine 20 mg had minimal H1RO, was not associated with subjective
sedation or objective impairment of psychomotor performance and was devoid of
treatment-related sedative AEs, thus satisfying relevant subjective, objective and PET
criteria as a non-sedating antihistamine.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Bilastine, a non-sedating, second generation
antihistamine, is approved for the treatment
of allergic rhinoconjunctivitis and urticaria.
• In clinical trials, the sedative properties of
bilastine and placebo were similar. Bilastine
has shown no effect on psychomotor
performance or driving ability.
• Bilastine histamine H1-receptor occupancy
(H1RO) has not yet been evaluated by
positron emission tomography (PET).
WHAT THIS STUDY ADDS
• This study is the first to measure cerebral
H1RO of bilastine 20 mg by PET. Bilastine
showed practically no cerebral H1RO
(−3.92 ± 14.39%).
• Results are in accordance with the clinical
classification of bilastine as a second
generation, non-sedating antihistamine.
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Introduction
First generation antihistamines (e.g. hydroxyzine) are still
widely used clinically, despite undesirable effects such as
central nervous system (CNS) impairment and strong seda-
tion [1, 2]. Even at recommended doses, first generation
agents may cause dangerous situations for individuals
who are driving, piloting planes or operating heavy
machinery [2–4]. Second generation antihistamines (e.g.
cetirizine, loratadine) may be ‘relatively non-sedating’, i.e.
they produce minimal cognitive and psychomotor dys-
function at recommended doses, but dose-related dys-
function at higher dosages, or truly non-sedating even at
high doses (e.g. fexofenadine). Many physicochemical
properties of drugs such as molecular weight, lipophilicity,
polar surface area and number of hydrogen bonds, in addi-
tion to being a substrate of P-glycoprotein, limit blood–
brain barrier penetration [1, 3, 5].
Studies of the CNS effects of antihistamines are often
conducted in healthy volunteers because the results can
be extrapolated to patients with allergic disease. Although
allergic mediators may alter blood–brain barrier perme-
ability, results from volunteers are good predictors of the
effects in patients [6]. The merits of subjective documen-
tation of drowsiness and objective CNS testing may be
limited in some situations by an individual’s motivation
or familiarity with tests [1]. Positron emission tomo-
graphy (PET) represents a major breakthrough, providing
a sensitive reference method for quantifying CNS pene-
tration. The histamine H1-receptor occupancy (H1RO) of
antihistamines can relate to psychometric and other tests
of CNS function [1, 7, 8]. Pooled analyses of clinical trial
data have confirmed a close correlation between PET-
determined H1RO and the incidence of sedation [2, 8].
H1RO >50% has been clearly linked with a high rate of
sleepiness and cognitive decline. After single dose oral
administration of various antihistamines, values of H1RO
vary widely up to about 75% with ketotifen 1 mg [3, 8].
Overall, three categories of antihistamine can be conven-
tionally defined according to H1RO intervals: non-sedating
(<20% occupancy), less sedating (20–50%) and sedating
(>50%) [2, 3].
Altogether, the non-sedating properties of antihista-
mines require full characterization according to subjec-
tive sleepiness recorded on scales such as the Stanford
Sleepiness Scale; objective assessments of cognitive and
psychomotor function (e.g. critical flicker fusion, choice
reaction time, digit symbol substitution test [DSST]); and
PET evaluation of H1RO <20% [1, 3]. Subjective sleepi-
ness should be determined in large scale, double-blind,
placebo-controlled studies, and assessments of cognitive
function (at least two tasks) should also be performed in
large study populations. No statistically significant differ-
ences should be observed between the test antihistamine
and placebo [3]. Various methods of PET imaging with
radiolabelled [11C]-doxepin have been used successfully
for quantification of H1RO; for example, a simplified refer-
ence tissue model approach and Logan graphical analysis
with reference tissue or arterial sampling [9–12].
The current crossover trial was designed to determine
H1RO in the brain, using [11C]-doxepin and PET, after single
dose oral administration of the second generation anti-
histamine bilastine (20 mg), the first generation agent
hydroxyzine (25 mg) and placebo, in healthy male volun-
teers. Bilastine is approved in several countries for the
treatment of allergic rhinoconjunctivitis (seasonal and per-
ennial) and urticaria [13]. It is a non-sedating and long-
acting antihistamine, with selective H1-receptor affinity,
and no affinity for other aminergic receptors [14, 15]. In
controlled clinical trials at the recommended therapeutic
dose of 20 mg once daily, the CNS effects and safety profile
of bilastine were similar to those of placebo; no significant
difference in the incidence of drowsiness was noted
between bilastine and placebo. Other clinical trials have
shown bilastine 40 mg day−1 to have no effect on
psychomotor performance or driving ability [16, 17]. As is
the case for fexofenadine, bilastine is also a P-glycoprotein
substrate and its physicochemical properties can limit
blood–brain barrier penetration [18]. The current study is
the first to assess brain H1RO by bilastine.
Methods
Study design
This was a phase I, double-blind, placebo-controlled,
crossover study, in which subjects were randomized to
one of six test-treatment sequences (two subjects per
sequence) comprising the three test compounds. A
screening visit was conducted within 3 weeks before the
first experimental session, and each subject participated in
three sessions. In each session, subjects received a single
oral dose of bilastine, hydroxyzine or placebo, followed by
intravenous [11C]-doxepin (Molecular Imaging Centre, CRC
Mar, Barcelona, Spain). To allow for washout of bilastine
and hydroxyzine, there was an interval of at least 1 week
between sessions. At 3–7 days after completion of all three
sessions, a final study visit was conducted which consisted
of a physical examination, assessment of laboratory and
urinary parameters and final safety evaluation. The total
study duration for each subject, including screening,
experimental sessions and washout, and the final study
visit, was at least 6–8 weeks.
The primary study end point was brain H1RO. Second-
ary outcome measures comprised plasma bilastine con-
centrations; subjective evaluation of sedation (drowsiness,
absent-mindedness, and sleepiness) assessed by visual
analogue scales [VAS 0–100 mm]; objective assessment of
psychomotor performance (DSST), physiological variables
(systolic and diastolic blood pressure, heart rate [mea-
sured using a Carescape™ V100 monitor, GE Healthcare,
Milwaukee, WI, USA] and oral temperature); and a safety
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evaluation which included adverse events (AEs) reported
spontaneously by subjects or detected by the study inves-
tigator. The DSST, a classical test designed to evaluate rec-
ognition and recording of visual information [18], is a
subset of the Adult Intelligence Scale-Revised [19] and has
been used widely to evaluate sedation induced by drugs
[20–22]. The three visual analogue scales selected are com-
monly used to evaluate clinical sedation in studies in
healthy subjects or patients, and have been used in previ-
ous studies of bilastine [23, 24] or sedatives [20, 21].
The study was approved by the Clinical Research
Ethical Committee, Parc de Salut MAR, and the Spanish
Medicines Agency, and was performed in accordance with
the Declaration of Helsinki (2008), Good Clinical Practices
of the International Conference on Harmonization (ICH)
and applicable laws and regulations (Royal Decree 223/
2004, Directive 2001/20/CE).
Subjects
Twelve healthy men, aged 20–39 (mean 26.2 ± 5.7) years
and with body mass index 22.4–27.0 (mean 24.7 ± 1.68)
kg m−2, participated in and completed the study. None of
the subjects smoked regularly (>5 cigarettes day−1). Pre-
study alcohol and caffeine consumption were <30 g day−1
and <5 cups day−1, respectively, and all participants had
negative pre-study urinary drug abuse screens. At the
initial screening visit, serology tests were negative for HIV
and hepatitis B and C, vital signs were normal and no sub-
jects had clinically significant laboratory abnormalities.
Written informed consent to participate was obtained
prior to any study-related procedure.
Test compound administration
The test compounds were single oral doses of bilastine
20 mg (Bilaxten® 20 mg, tablets; FAES FARMA, S.A., Leioa-
Bizkaia, Spain), hydroxyzine 25 mg (Atarax® 25 mg, tablets;
UCB Pharma, S.A., Barcelona, Spain) and placebo. For all
treatments, tablets were encapsulated in opaque capsules
to ensure blinding . Each test compound was administered
with 250 ml of water.
Experimental sessions (PET measurement)
A schematic overview of the PET study design is shown in
Figure 1. Subjects were admitted to the clinical research
unit the evening before each experimental session. A
magnetic resonance imaging scan was performed that
evening. The following morning, subjects were woken at
07.00 h. Baseline and vital signs were recorded, and a seda-
tion questionnaire (VAS) and DSST were completed. The
test compound was administered at 08.00 h. One hour
later, subjects were moved to the molecular imaging
centre for PET examination. PET was performed using
a Siemens ECAT EXACT HR+ scanner (Siemens, S.A.,
Madrid, Spain). The image acquisition protocol was simi-
lar to that used in previous studies assessing H1RO by
antihistamines [25].
Before intravenous administration of [11C]-doxepin,
each subject was placed on the PET couch and under-
went a 10 min transmission scan for subsequent correc-
tion of transmission attenuation. After injection of the
radioligand, emission acquisition was performed for
90 min (including 26 frames: 8 × 15 s, 3 × 60 s, 5 × 120 s,
5 × 300 s and 5 × 600 s). The radioactive dose did
not exceed 8 mCi (296 MBq) per scan. [11C]-doxepin
radiochemical purity was ≥95% and its specific radio-
activity at the time of injection was 50.12 ± 19.00
GBq μmol−1. The injected dose and cold mass of
[11C]-doxepin were 7.11 ± 0.63 mCi and 3.68 ± 2.45 μg,
respectively.
After PET scans, subjects returned to the clinical
research unit where they remained until 12 h after study
drug administration. Blood samples (5 ml Vacutainer tube
containing sodium heparin) for measurement of plasma
bilastine concentrations were taken at 0 h (drug adminis-
tration), 1 h (PET start), 1.75 h (mid-PET) and 2.5 h (PET
end). These time points were selected to ensure that PET
data were recorded in the interval next to the maximum
exposure to bilastine (tmax = 1.3 h) [26]. Bilastine is rapidly
absorbed after oral administration, with a tmax of 1–1.5 h
and a half-life of 10–12 h [26, 27]. Hydroxyzine has a tmax of
2 h and an elimination half-life of 20 ± 4.1 h [28]. Although
plasma concentrations of hydroxyzine were not deter-
mined, PET data were recorded in the interval around the
published tmax (2.1 h) [29]. Vital signs were recorded at 0, 1,
2.5, 6 and 12 h. The sedation questionnaire and DSST were
completed at 0, 1, 2.5 and 6 h.
Image and data analysis
PET images were reconstructed by filtered retroprojection
and were corrected by attenuation, scatter, random coin-
cidences and dead time, using algorithms from the
scanner manufacturer. Dynamic PET images were cor-
rected for motion by realigning each time frame to the
averaged frame using a mutual information-based algo-
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Figure 1
PET study design. PL: Blood sampling for determination of plasma
concentrations of bilastine. CNS: central nervous system assessment
(subjective evaluation of sedation: drowsiness, absent-mindedness and
sleepiness, assessed by visual analogue scales [0–100 mm]; objective
assessment of psychomotor performance [digit symbol substitution
test])
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Trust Centre for Neuroimaging; http://www.fil.ion.ucl
.ac.uk/spm) and registered to the subject’s MRI. Regions of
interest (ROIs) were defined through non-linear registra-
tion (using SPM8) of a template MRI and the correspond-
ing atlas (Harvard–Oxford atlas included with FSL 4.1;
http://www.fmrib.ox.ac.uk/fsl). ROIs were frontal, occipital,
parietal, temporal, insula and cerebellar grey matter. A
grey matter map obtained from the subject’s MRI scan was
applied in order to segment each of the cortical ROIs. Each
ROI was then applied to the dynamic PET data to derive
regional time–activity curves. Time–activity curves were
processed by graphical methods [9], using the cerebellum
as the reference region to obtain ‘binding potential’ for the
radioligand at baseline and after drug administration [12].
The graphical methods used for image analysis permitted
avoidance of arterial blood sampling from subjects; these
methods have been described previously and have been
validated for H1RO determination [10]. Total binding
potential was defined as the mean binding potential value
obtained from the five ROIs (frontal, occipital, parietal,
temporal, insula).
H1RO was estimated according to equation 1:
H RO












All statistical analyses were conducted using IBM SPSS
version 18 software (IBM Spain S.A., Barcelona, Spain) and
with the significance value (P) set at 0.05.
Repeated measures analysis of variance (ANOVA) with
treatment as factor was used to assess the difference
between mean total binding potential and binding poten-
tial in each ROI. If statistically significant differences were
identified, Tukey post hoc tests were applied. The Wilcoxon
matched-pairs, signed-rank test was used to determine
whether significant differences existed between bilastine
and hydroxyzine for H1RO.
Although the protocol employed is not the most
appropriate to establish a possible H1RO–plasma concen-
tration relationship, a linear regression between plasma
concentrations (AUC(0,2.5h)) vs. binding potential (mean
from five ROIs) was calculated as the optimal approach.
Bilastine AUC was calculated by the trapezoidal rule.
Values from physiological variables, subjective seda-
tion (drowsiness, absent-mindedness, sleepiness) and
DSST (number of correct responses) across the study were
transformed to differences from baseline. For each vari-
able, the peak effect in the first 6 h (sedation and
psychomotor performance) or 12 h (physiological variable)
after administration and the 6 h (sedation and DSST) or
12 h (physiological outcomes) AUC of effects vs. time, cal-
culated by the trapezoidal rule, were determined. These
transformations were analyzed by one way repeated
measures ANOVA, with test drug as factor. Post hoc multiple
comparisons were performed using the Tukey test. Finally,
a detailed comparison of the time course of effects was
conducted using two way repeated measures ANOVA, with
treatment and time as factors. Whenever treatment condi-
tion or the treatment condition × time interaction was sta-
tistically significant, multiple Tukey post hoc comparisons
were performed at each time point using the mean square
error term of the treatment condition × time interaction.
Any changes in vital signs from screening to the final study
visit were evaluated by paired Student’s t-test. Descriptive
statistics were used to characterize adverse events.
Results
Binding potential and histamine
H1-receptor occupancy
Total binding potential was defined as the mean value
obtained from the five ROIs. Mean (± SD) total binding
potential for [11C]-doxepin was significantly greater with
the bilastine than hydroxyzine (0.26 ± 0.07 vs. 0.13 ± 0.07;
P < 0.01). No significant difference in mean total binding
potential was noted between bilastine and placebo
(0.26 ± 0.07 vs. 0.26 ± 0.08, Table 1). The same findings
were evident in each of the five ROIs (P < 0.01 for bilastine
vs. hydroxyzine, Figure 2). Standard and coloured PET
images, obtained after administration of bilastine,
hydroxyzine or placebo, are presented in Figure 3.
Based on binding potential values (see equation 1),
mean (± SD) total H1RO by bilastine was significantly
lower than that by hydroxyzine (–3.92 ± 14.39% vs.
53.95 ± 14.13%, P < 0.01, Figure 4). The same was true for
mean H1RO values in all five ROIs (P < 0.01 for all bilastine–
hydroxyzine differences, Table 2).
Plasma bilastine concentrations
Mean plasma bilastine concentrations were 140.4 ±
92.7 ng ml−1 (1 h post-dose), 116.9 ± 73.8 ng ml−1 (1.75 h),
and 108.5 ± 55.9 ng ml−1 (2.5 h). Mean bilastine
AUC(0,2.5h) was 112.7 ± 64.8 ng ml−1·h, with a range of
2.6–502.3 ng ml−1·h. No significant linear correlation was
noted between AUC(0,2.5h) and mean total binding
potential for bilastine (r2 = 0.063, P > 0.05, Figure 5).
Subjective evaluation of sedation and
psychomotor performance
No significant differences were noted between bilastine,
hydroxyzine and placebo with regard to mean maximum
changes from baseline in VAS scores (Emax) for drowsiness,
absent-mindedness and sleepiness or in DSST scores (data
not shown). In addition, for all subjective outcomes and
DSST, no significant differences were observed between
the three study treatments in terms of AUC values. For
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sedation and DSST, maximum scores were attained at 2.5 h
post-dose, but no significant between-treatment differ-
ences were noted.
Safety evaluation
Ten study participants (83.3%) reported at least one AE,
but none were serious. A total of 26 AEs were reported
(Table 3): four subjects had one AE, one had two AEs, two
had three AEs, one had four AEs and two subjects had five
AEs. Most AEs were mild (84.6%), while the remainder
were moderate in intensity. The most frequent AEs were
nervous system disorders; headache occurred in four sub-
jects. Overall, nine AEs were reported with bilastine, seven
with hydroxyzine and seven with placebo; three other AEs
(odynophagia, itchy throat, common cold) occurred
between screening and the first dose of study medication.
No sleepiness or sedation was reported after bilastine
administration, but there were two reports of sedation
after hydroxyzine, and one report of sleepiness after
placebo. Overall, two AEs (sedation after hydroxyzine)
were considered probably related to antihistamine admin-
istration, and six AEs (headache, diarrhoea, vomiting) were
considered possibly related.
No differences were observed among treatments with
regard to vital signs during the experimental sessions.
Also, no clinically significant changes in laboratory param-
eters and vital signs occurred between selection and final
visits.
Discussion
Guidelines from the Consensus Group On New-Generation
Antihistamines (CONGA) clearly stipulate that for an anti-
histamine to be classed as non-sedating, at least three key
factors require assessment: self-reporting of sleepiness in
Table 1
Binding potential values (mean ± SD) obtained from five regions of interest (ROIs). The total binding potential (mean ± SD) is the average of the five ROIs
Binding potential (from Logan plot Binding potential = DVR – 1)
Region of Interest Placebo Bilastine 20 mg Hydroxyzine 25 mg
Frontal 0.278 ± 0.091 0.276 ± 0.075 0.122 ± 0.067
Occipital 0.177 ± 0.070 0.193 ± 0.078 0.088 ± 0.063
Parietal 0.273 ± 0.091 0.286 ± 0.087 0.141 ± 0.063
Temporal 0.214 ± 0.085 0.208 ± 0.068 0.094 ± 0.069
Insula 0.338 ± 0.091 0.339 ± 0.070 0.205 ± 0.086
Total 0.256 ± 0.081 0.260 ± 0.072 0.130 ± 0.067
Mean difference and 95% CI, placebo vs. bilastine and hydroxyzine
Mean difference and 95% CI bilastine vs. hydroxyzine









































Mean (± SD) binding potential of the radioligand [11C]-doxepin after single dose antihistamine or placebo administration. Data shown are for five individual
regions of interest (ROIs), and mean total binding potential for the ROIs combined. *P < 0.01 for all bilastine–hydroxyzine and all hydroxyzine–placebo
differences; no significant bilastine–placebo differences. , placebo; , bilastine 20 mg; , hydroxyzine 25 mg
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Figure 3
Co-registered magnetic resonance image and [11C]-doxepin positron emission tomography images after administration of placebo, bilastine (20 mg) and






































Mean (± SD) brain histamine H1-receptor occupancy (H1RO) after single dose antihistamine administration. Data shown are for five individual regions of
interest (ROIs), and mean total H1RO for the ROIs combined. P < 0.01 for all bilastine–hydroxyzine differences. , bilastine 20 mg; , hydroxyzine 25 mg
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antihistamine-treated individuals (it is unscientific to use
this measure alone to define the sedative properties of
antihistamines [2]); objective evaluation of psychomotor
performance and cognitive function through tests such as
critical flicker fusion, choice reaction time and DSST; and
PET assessment of H1RO [1]. PET assessment provides a
sensitive and absolute measure of blood–brain barrier
penetration and H1RO [1, 7, 8]. It is widely acknowledged
that H1RO <20% is a requirement for classification of anti-
histamines as non-sedating [7, 30].
Table 2
Mean (± SD) brain histamine H1-receptor occupancy values (%) for bilastine and hydroxyzine in 12 healthy volunteers
Receptor occupancy (%)
Region of interest Bilastine 20 mg (*) Hydroxyzine 25 mg
Frontal −2.41 ± 20.97 58.91 ± 13.37
Occipital −8.07 ± 19.60 56.96 ± 21.95
Parietal −7.17 ± 20.74 49.93 ± 12.29
Temporal 0.38 ± 12.61 62.83 ± 20.60
Insula −2.32 ± 11.83 41.12 ± 11.10
Total −3.92 ± 14.39 53.95 ± 14.13
Mean difference and 95% CI bilastine vs. hydroxyzine
Median difference and 95% CI bilastine vs. hydroxyzine
57.870% (42.664%, 73.075%)
54.228% (43.713%, 78.819%)
*P < 0.01 vs. hydroxyzine.
0.50
0 50
r2 = 0.0634 (NS)
100 150 200 250 300 350 400 450 500 550


































Linear regression between individual bilastine AUC(0,2.5h) (ng ml−1·h) values and total binding potential (average from five regions of interest). The r2 value
indicates no significant linear relationship between parameters. , bilastine 20 mg; , linear (bilastine 20 mg)
Table 3
Adverse events (AEs) considered possibly or probably related to study treatment†
System organ class AE incidence (%)‡
Number of AEs
Placebo Bilastine Hydroxyzine Total
Gastrointestinal disorders 15.4 1 3* 0 4
Diarrhoea 7.7 1 1* 0 2
Vomiting 7.7 0 2* 0 2*
Nervous system disorders 26.9 2 2* 3* 7
Headache 15.4 1 2* 1* 4
Sleepiness (somnolence) 3.9 1 0 0 1
Sedation 7.7 0 0 2* 2*
†Indicated by asterisk (*). ‡% of all AEs (26).
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The current, placebo-controlled PET study com-
pared brain H1RO by bilastine with that by the first
generation antihistamine hydroxyzine in healthy volun-
teers, using a methodology similar to that adopted in
several previous PET studies [7, 8, 12, 25, 31–33]. Brain
H1RO values after administration of single oral doses of
various other antihistamines have been reported previ-
ously: bepotastine 10 mg, 15–17% [12, 33], cetirizine
20 mg, 26% [31], d-chlorpheniramine 2 mg, 50–77% [7, 8,
25], diphenhydramine 30–50 mg, 45–56% [12, 33],
ebastine 10 mg, 10% [25], fexofenadine 120 mg, −0.1% [12,
33], hydroxyzine 30 mg, 68% [29], ketotifen 1 mg, 72% [32],
loratadine 10 mg, 12% [8], olopatadine 5 mg, 15% [32] and
terfenadine 60 mg, 17% [2].
These previous trials have clearly highlighted the
rationale for full characterization of the sedative or non-
sedative potential of antihistamines. Sedating antihista-
mines increase the likelihood of accidents while driving,
flying planes or operating heavy machinery [2–4]. PET
studies have pointed to the possibility of hangover
sedation the day after evening administration of diphen-
hydramine as a sleep aid [33]. PET studies have also
facilitated the definition of ‘relatively non-sedating’ anti-
histamines (e.g. cetirizine, loratadine) which are non-
sedating at therapeutic doses, but may cause sedation
when used at higher doses (e.g. in ‘over-compliant’
patients who take greater than recommended doses of
antihistamines to try to relieve symptoms faster and to a
greater degree) [1, 3, 4].
The current trial represents the first PET study to
investigate brain H1RO by bilastine. Results showed statis-
tically significant lower mean binding potential values in
all brain ROIs and on average (total binding potential),
with hydroxyzine 25 mg vs bilastine 20 mg, and also with
hydroxyzine vs placebo. Total binding potential was
0.256 ± 0.081 for placebo, 0.260 ± 0.072 for bilastine
20 mg and 0.130 ± 0.067 for hydroxyzine 25 mg. No sig-
nificant differences in total binding potential or in each
individual ROI were found between bilastine and placebo.
Likewise, irrespective of treatment, there was con-
sistency in the binding potential results. Under the con-
ditions used in our study, the occipital region was the
region with minimum binding potential values (indicat-
ing lower H1-receptor density), and the insula region was
the region with the highest binding potential values
(indicating higher H1-receptor density). We also observed
that the frontal and parietal regions (particularly the
frontal region) could possibly represent the total binding
potential of the five ROIs, as mean binding potential
values obtained in each individual region were close to
the total binding potential. Regarding H1RO it can be
summarized that lower H1RO in all brain regions and on
average (total H1RO) was observed with bilastine com-
pared with hydroxyzine. These differences were statisti-
cally significant (P < 0.01). Total H1RO was −3.92 ± 14.39%
for bilastine 20 mg compared with 53.95 ± 14.13% for
hydroxyzine 25 mg. In this study, it was also noted that
the frontal region may be considered to be a representa-
tive region of the five brain ROIs assessed, as demon-
strated by the similarity in the magnitude of binding
potential data vs. mean total binding potential. It is also
important to note that total H1RO for bilastine was less
than zero. To date, the only other non-sedating antihis-
tamine reported to have negative H1RO is fexofenadine
[31]. It is interesting to speculate whether a new category
of non-sedating antihistamines, with negative H1RO, can
be proposed.
As shown in Figure 5, there was no significant linear
relationship between individual values of the AUC(0,2.5h)
of bilastine plasma concentrations and the mean total
binding potential. A correlation coefficient (r2) of 0.0634
(P > 0.05, NS) was calculated. Nevertheless, a dose–
response study would be the best approach to investigate
the relationship between bilastine plasma concentrations
and total binding potential. The mean total binding poten-
tial for placebo (0.2561) fits perfectly with the regression
line for bilastine AUC(0,2.5h) values = 0 ng ml−1 h.
The PET assessments were performed between 1–2.5 h
post-drug administration in order to obtain measures
around the tmax. The results concur in the case of bilastine.
A limitation of the study is that hydroxyzine blood concen-
trations were not determined and the value for tmax
was based on previous studies. Bilastine plasma concen-
trations were lower than expected in one subject and
the possibility of excluding his data from the final
analysis was considered. Analyses were repeated, again
showing low levels of bilastine, and, after considering
the absence of correlation between bilastine plasma
AUC(0,2.5h) and total binding potential, they were finally
included, although we were aware that this would
contribute to a greater dispersion of pharmacokinetic
data. The reason for such low concentrations of bilastine
in the subject is still uncertain, as the record card showed
nothing relevant and it could not be explained due
to vomiting or other circumstances during the experi-
mental session. Low concentrations in this subject may
relate to low bioavailability of bilastine, delayed peak
plasma concentration or individual genetic variation in
P-glycoprotein.
No significant differences were noted between test
compounds with regard to VAS ratings of drowsiness,
absent-mindedness and sleepiness or objective assess-
ment of the number of correct responses on the DSST,
probably due to inter-subject variability and limited
sample size. Although the receptor occupancy of hydro-
xyzine was >50%, significant CNS effects were not
observed which was an unexpected result for a sedating
antihistamine with an overall proportional impairment
ratio (PIR) of 2.43 [34]. One explanation for this
observation is that the assay used in the current study
was not the most appropriate for assessing CNS effects
after administration of hydroxyzine. Moreover, the 2.5 h
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assessment was conducted after individuals had been
lying down and quiet for a period of 90 min and this may
have impacted on the observation of CNS effects. Most
subjects sleep during the PET. Indeed, with a mean H1RO
of 67.6%, hydroxyzine 30 mg was previously shown to
have a significant effect, compared with placebo, on sub-
jective sleepiness only at a single time point (2 h) but not
at 2.5 or 3 h [29]. In another study, 12 h after administra-
tion, the mean H1RO for diphenhydramine 50 mg was sig-
nificantly greater than that for bepotastine 10 mg (44.7%
and 16.6%, respectively; P < 0.01), yet there were no sig-
nificant between treatment differences in subjective
sleepiness [33]. It is widely acknowledged that assess-
ment of subjective sleepiness is affected by numerous
internal and environmental factors and, in isolation, is not
the most reliable method for assessing the sedative effect
of antihistamines but is useful in real conditions.
The antihistamines in the current trial were well toler-
ated. Overall, 26 AEs were reported, and all were mild or
moderate in intensity. Only eight AEs were considered
probably or possibly related to antihistamine admini-
stration: headache (two cases after bilastine, one after
hydroxyzine), diarrhoea (1, 0), vomiting (2, 0) and sedation
(0, 2). No clinically significant changes in laboratory param-
eters or vital signs occurred during the trial.
Altogether, data indicated that bilastine 20 mg did
not cross the blood–brain barrier and did not reach levels
sufficient to compete with [11C]-doxepin binding at
H1-receptors in any of the five ROIs. These results, high-
lighting a lack of CNS activity for bilastine, are corrobo-
rated by secondary end point safety data, i.e. bilastine
was not associated with AEs of sleepiness or sedation
considered possibly or probably related to treatment.
Data from other studies have also indicated a lack of
effect for bilastine on psychomotor performance or
driving ability at twice the maximum recommended
dosage [16, 23].
In summary, brain H1RO by bilastine (after a 20 mg
dose) was significantly lower than that by hydroxyzine
(25 mg) in all five cerebral cortex ROIs, and overall.
Bilastine was not associated with subjective sedation, or
objective impairment of psychomotor performance, and
was safe and well tolerated and devoid of treatment-
related, sedative AEs. Thus, bilastine 20 mg satisfied
relevant subjective, objective and PET criteria to be con-
sidered as a reliable non-sedating antihistamine.
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